JanOne Earns US Patent for the Use of its Novel Formulation of Low-Dose Naltrexone, Jan123, to Treat Chronic Pain

/PRNewswire/ -- JanOne (Nasdaq: JAN), the visionary biotech company dedicated to discovering non-addictive treatments for pain, as well as causes of pain, has...

Related Keywords

Amol Soin ,Tony Isaac ,Tony Giordano ,Janone Inc ,Exchange Commission ,Us Patent Office ,Broad Patent Coverage ,Major Milestone ,Commercial Success ,Chief Scientific ,Private Securities Litigation Reform Act ,